Aurobindo Pharma receives US FDA nod for rivastigmine capsules
The approved product, rivastigmine tartrate capsules, is generic version of Novartis' Exelon and has an estimated market size of $ 26.7 million
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (US FDA) to manufacture and market rivastigmine tartrate capsules (1.5 mg, 3 mg, 4.5 mg and 6 mg). The product, a generic version of Novartis Pharmaceuticals Corporation’s Exelon capsules, is expected to be launched in Q1 FY16-17.
The approved product has an estimated market size of $ 26.7 million for the twelve months ending January 2016, according to IMS.
The approved product has an estimated market size of $ 26.7 million for the twelve months ending January 2016, according to IMS.